Attention AACR Annual Meeting 2017 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 15 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 12 13 14 15 presentations: 1 to 25 of 355
Immunity against cancer: How to be enhanced?
Jolanda de Vries
Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 3:00 PM-4:30 PM
Gene-modified T cells as biotherapeutics for cancer
Stephen Gottschalk
Baylor College of Medicine, Houston, TX, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 3:00 PM-4:30 PM
Immune checkpoint inhibitors: Opportunities and challenges
Mary L. (Nora) Disis
University of Washington, Seattle, WA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 3:00 PM-4:30 PM
Mutation-driven drug development (targeted agents) vs. immunotherapeutics development
Alexander M Eggermont
Gustave Roussy Cancer Institute, Villejuif, Paris-Sud, France
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
CAR therapy for cancer: Emerging insights
Crystal L. Mackall
National Cancer Institute, Bethesda, MD, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
TIL therapy in the era of immune checkpoint blockade
John B.A.G. Haanen
Netherlands Cancer Inst., Amsterdam, Netherlands
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
Engineering T cells with introduced TCRs to effectively target tumors
Philip D Greenberg
Fred Hutchinson Cancer Res. Ctr. & Univ. of Washington, Seattle, WA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
Targeting driving genomic mutations in breast cancer
José Baselga
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 8, 2015 8:00 AM-10:00 AM
Title to be announced
Jeffrey A. Engelman
Massachusetts General Hospital, Boston, MA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 8, 2015 8:00 AM-10:00 AM
Basket studies: Lessons learned and future directions
David Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 8, 2015 8:00 AM-10:00 AM
Dissecting colorectal cancer in multiple targetable subtypes
Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain
from 2015 Molecular Targets and Cancer Therapeutics conference on November 8, 2015 8:00 AM-10:00 AM
The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas
Howard Burris
Sarah Cannon Research Institute, Nashville, TN, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 8, 2015 8:00 AM-10:00 AM
Introduction
Lee J. Helman
National Cancer Institute, Bethesda, MD, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 4:45 PM-6:15 PM
National-scale cancer sequencing and treatment response data integration in The Netherlands
Edwin Cuppen
University Medical Center Utrecht, Utrecht, Netherlands
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 4:45 PM-6:15 PM
Assigning clinical meaning to genomic data for cancer precision medicine
Nikhil Wagle
Dana-Farber Cancer Institute, Brookline, MA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 4:45 PM-6:15 PM
Delivering of the promise of personalized medicine
Gordon B. Mills
The University of Texas MD Anderson Cancer Center, Houston, TX, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 4:45 PM-6:15 PM
Returning germline results to cancer patients
Sharon E. Plon
Baylor College of Medicine, Houston, TX, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 4:45 PM-6:15 PM
Updates on engineered T cells as cancer therapies
Carl H. June
Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 8:00 AM-9:35 AM
Impact of gut microbiota in cancer development and therapeutics
Laurence Zitvogel
Gustave Roussy Cancer Center, Villejuif, France
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 8:00 AM-9:35 AM
Acquisition of resistance to anti-EGFR therapy drives genomic heterogeneity and lesion-specific responses in colorectal cancer
Giulia Siravegna
University of Torino - IRCCS Candiolo, Candiolo, Italy
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 3:30 PM-4:10 PM
Identification of a potent and selective chemical probe for exploring the role of CDK8/19 in cancer biology
Paul A. Clarke
Cancer Research UK Unit, The Institute of Cancer Research, London, United Kingdom
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 3:30 PM-4:10 PM
Novel ceritinib resistance mechanisms: new resistant mutation, fibroblast growth factor receptor 3 overexpression and cMET amplification-mediated ceritinib resistance
Ryohei Katayama
Japanese Foundation for Cancer Research, Tokyo, Japan
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 3:30 PM-4:10 PM
The radiology reading room of the future
Robert J. Gillies
Moffitt Cancer Center & Research Institute, Tampa, FL, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 4:15 PM-6:15 PM
Incorporating molecular imaging methods in early drug development
E. G. Elisabeth De Vries
Univ. Medical Ctr. Groningen, Groningen, Netherlands
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 4:15 PM-6:15 PM
Radiomics: The promise of imaging for personalized medicine
Hugo Aerts
Brigham & Women's Hospital, Boston, MA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 4:15 PM-6:15 PM
<< first | < prev page: of 15 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 12 13 14 15 presentations: 1 to 25 of 355